Literature DB >> 34086286

Expression and Purification of tRNA/ pre-miRNA-Based Recombinant Noncoding RNAs.

Mei-Juan Tu1, Halley K Wright1, Neelu Batra1, Ai-Ming Yu2.   

Abstract

Research on RNA function and therapeutic potential is dominated by the use of chemoengineered RNA mimics. Recent efforts have led to the establishment of novel technologies for the production of recombinant or bioengineered RNA molecules, which should better recapitulate the structures, functions and safety profiles of natural RNAs because both are produced and folded in living cells. Herein, we describe a robust approach for reproducible fermentation production of bioengineered RNA agents (BERAs) carrying warhead miRNAs, siRNAs, aptamers, or other forms of small RNAs, based upon an optimal hybrid tRNA/pre-miRNA carrier. Target BERA/sRNAs are readily purified by fast protein liquid chromatography (FPLC) to a high degree of homogeneity (>97%). This approach offers a consistent high-level expression (>30% of total bacterial RNAs) and large-scale production of ready-to-use BERAs (multiple to tens milligrams from 1 L bacterial culture).

Entities:  

Keywords:  Bacteria; Bioengineering; Expression; Fast protein liquid chromatography (FPLC); Noncoding RNA (ncRNA); Pre-miRNA; Purification; Small interfering RNA (siRNA); microRNA (miR); tRNA

Mesh:

Substances:

Year:  2021        PMID: 34086286      PMCID: PMC9516694          DOI: 10.1007/978-1-0716-1499-0_18

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  21 in total

1.  Recombinant RNA technology: the tRNA scaffold.

Authors:  Luc Ponchon; Frédéric Dardel
Journal:  Nat Methods       Date:  2007-06-10       Impact factor: 28.547

2.  A generic protocol for the expression and purification of recombinant RNA in Escherichia coli using a tRNA scaffold.

Authors:  Luc Ponchon; Geneviève Beauvais; Sylvie Nonin-Lecomte; Frédéric Dardel
Journal:  Nat Protoc       Date:  2009-05-28       Impact factor: 13.491

Review 3.  The current state and future directions of RNAi-based therapeutics.

Authors:  Ryan L Setten; John J Rossi; Si-Ping Han
Journal:  Nat Rev Drug Discov       Date:  2019-06       Impact factor: 84.694

Review 4.  The chemical evolution of oligonucleotide therapies of clinical utility.

Authors:  Anastasia Khvorova; Jonathan K Watts
Journal:  Nat Biotechnol       Date:  2017-02-27       Impact factor: 54.908

5.  Bioengineering of a single long noncoding RNA molecule that carries multiple small RNAs.

Authors:  Hannah Petrek; Neelu Batra; Pui Yan Ho; Mei-Juan Tu; Ai-Ming Yu
Journal:  Appl Microbiol Biotechnol       Date:  2019-06-11       Impact factor: 4.813

Review 6.  Therapeutic Antisense Oligonucleotides Are Coming of Age.

Authors:  C Frank Bennett
Journal:  Annu Rev Med       Date:  2019-01-27       Impact factor: 13.739

7.  Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer Cells.

Authors:  Peng-Cheng Li; Mei-Juan Tu; Pui Yan Ho; Joseph L Jilek; Zhijian Duan; Qian-Yu Zhang; Ai-Xi Yu; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2017-10-23       Impact factor: 3.922

8.  Rapid production of novel pre-microRNA agent hsa-mir-27b in Escherichia coli using recombinant RNA technology for functional studies in mammalian cells.

Authors:  Mei-Mei Li; Wei-Peng Wang; Wen-Juan Wu; Min Huang; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2014-08-26       Impact factor: 3.922

9.  Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models.

Authors:  Mei-Juan Tu; Pui Yan Ho; Qian-Yu Zhang; Chao Jian; Jing-Xin Qiu; Edward J Kim; Richard J Bold; Frank J Gonzalez; Huichang Bi; Ai-Ming Yu
Journal:  Cancer Lett       Date:  2018-10-30       Impact factor: 8.679

10.  Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering.

Authors:  Jesper B Bramsen; Jørgen Kjems
Journal:  Front Genet       Date:  2012-08-20       Impact factor: 4.599

View more
  3 in total

1.  Bioengineered RNA Therapy in Patient-Derived Organoids and Xenograft Mouse Models.

Authors:  Mei-Juan Tu; Colleen M Yi; Gavin M Traber; Ai-Ming Yu
Journal:  Methods Mol Biol       Date:  2022

2.  Bioengineered miR-34a modulates mitochondrial inner membrane protein 17 like 2 (MPV17L2) expression toward the control of cancer cell mitochondrial functions.

Authors:  Wan-Rong Yi; Mei-Juan Tu; Ai-Xi Yu; Jun Lin; Ai-Ming Yu
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

Review 3.  MicroRNAs in the Regulation of Solute Carrier Proteins Behind Xenobiotic and Nutrient Transport in Cells.

Authors:  Colleen Yi; Ai-Ming Yu
Journal:  Front Mol Biosci       Date:  2022-06-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.